X.T.L. Biopharmaceuticals Ltd ADR Dossier
Qualitative Analysis
Business overview
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) is an Israel-based intellectual property (IP) portfolio company focused on the acquisition and development of pharmaceutical assets for autoimmune diseases and data-driven technology platforms. The company's legacy biopharmaceutical asset is hCDR1, a Phase II-ready synthetic peptide designed as a disease-specific treatment to modify the autoimmune process in systemic lupus erythematosus (SLE) and Sju0000gren's syndrome. XTL operates primarily under an asset-focused model, sublicensing its hCDR1 IP portfolio while actively pursuing strategic collaborations and acquisitions to expand into high-value therapeutic and technology sectors.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Implementing a comprehensive compliance plan to address multiple Nasdaq listing deficiencies, including the late filing of Form 20-F for the year ended December 31, 2025, falling below the minimum $2.5 million stockholders' equity requirement, and failing to maintain the $1 minimum bid price standard.
Expected impact: Securing the company's continued listing on the Nasdaq Capital Market and avoiding stock suspension/delisting.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To establish a leading psychedelic biotechnology platform. Psyga brings a licensed, GMP-ready pharmaceutical manufacturing facility, a proprietary library of over 180 mushroom strains, and seven approved Phase 2a human clinical trials across mental health, neurological, and addiction indications.
Financial impact: All-stock transaction with no cash paid at closing. Psyga shareholders will receive ADSs representing 40% of XTL's outstanding share capital post-closing, with up to an additional 30% contingent on achieving three clinical and commercial milestones. Supported by a committed $1.5 million private placement.
To acquire an 85% stake in NeuroNOS Ltd. from Beyond Air, Inc., positioning XTL in the autism therapeutics market. NeuroNOS pioneers disease-modifying therapeutics targeting Autism Spectrum Disorder (ASD) and neuro-oncology, holding two FDA Orphan Drug Designations.
Financial impact: Consideration consists of $1 million in cash, the issuance of ADSs representing 19.99% of XTL's outstanding share capital, and milestone-based contingent payments of up to $32.5 million ($5.5 million clinical/regulatory and $26 million commercial).
To expand XTL's intellectual property portfolio into ethical AI web data solutions for artificial intelligence and business intelligence applications.
Financial impact: XTL paid $430,000 in cash and issued ADSs representing 44.6% of XTL's outstanding share capital post-transaction, plus milestone-contingent warrants. Supported by a completed $1.5 million private placement.